Please assess the completion status of the following clinical trial:

Trial Title: ST266 Versus Standard Care In Treating Partial Thickness Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A signed IRB (Institutional Review Board)- approved Informed Consent Form;~* 18 - 65 years of age;~* Two (2) similar, non-contiguous, partial-thickness burn wounds between 50 cm2 and 250 cm2 in area with blisters removed in a Total Body Surface Area(TBSA) burn of less than or equal to 40% TBSA;~* Burns must be thermal burns of flame or scald etiology;~* Patient must present to the burn center within 8 hours of injury;~* Normal creatinine and bilirubin levels;~* If capable of bearing children, patient must be using a medically accepted means of birth control and have a negative serum pregnancy test;~* Willing to participate in the clinical study and comply with the requirements of the trial.~Exclusion Criteria:~* The two (2) chosen wounds must not be full-thickness (extending through the dermis into the subcutaneous tissue);~* Thermal burn from chemical, electrical or radiation causes;~* Neither the study wound nor the comparator wound can be \< 50 cm2 or \>250 cm2 in size and cannot be on the face or hands;~* Patients with significant pulmonary injury, i.e., smoke inhalation injury requiring ventilator support;~* Patients with diabetes;~* Patients with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent;~* Abnormal bilirubin, liver function studies (i.e., Alanine transaminase (ALT); Aspartate transaminase (AST)\> 2.0 times normal);~* Abnormal serum creatinine, receiving hemodialysis or peritoneal dialysis;~* Active cancer or a history of cancer in the 5 years prior to signing the informed consent form (history of basal cell carcinoma is allowed);~* Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;~* History of non-compliance with treatment or clinical visit attendance.~* Patients whose burns were previously treated with anything other than ice, cold water or dry dressing.~* Participation in an investigational trial within 30 days of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ST266 1 (Type: EXPERIMENTAL): Topical treatment every other day
- ST266 2 (Type: EXPERIMENTAL): Topical treatment every 4th day
- ST266 3 (Type: EXPERIMENTAL): Topical treatment every 7th day

Based on this trial design, predict the completion outcome and termination type (if applicable).